Dr Carpenter is a Cardiologist and Clinical Lead for Cardiology at Poole Hospital with a specialist interest in cardio-oncology and cardiovascular imaging. He qualified in 1996 from Guy's and St. Thomas' Hospitals before training in Cardiology. He was appointed to a National Institutes of Health (NIH) funded research Fellowship at the Royal Brompton Hospital in London in 2007, followed by a Clinical Fellowship in imaging and heart failure at University Hospitals Southampton before taking up a locum consultant position in cardiovascular MRI, inherited cardiac diseases and cardio-oncology at the Brompton where he assisted Dr Alex Lyon in setting up the specialist cardio-oncology service. 

Since starting in Poole in 2013, he has overseen the ongoing development of a comprehensive local cardiac MRI, CT and echo service with an extended outreach to neighbouring institutions as well as providing cardio-oncology input and imaging services for cancer patients in the Dorset Cancer Centre. His research interests include non-invasive imaging, in particular cardiac MRI with a focus on haematological (red cell) disorders leading to cardiac iron overload and its assessment. He has been an invited speaker at multiple local, national and international meetings. He is passionate about cardiology in general with a particular interest in imaging, both advanced echocardiography and cross-sectional imaging (cardiac CT and MRI). He is an examination board member for the European Association of Cardiovascular Imaging (EACVI) Section CMR and is a founding board member of the British Cardio-Oncology Society (BC-OS).

Dr. Dent is a Medical Oncologist at The Ottawa Hospital Cancer Centre and Professor in the Department of Medicine at the University of Ottawa.  She obtained her MD at McMaster University and completed her postgraduate training in Internal Medicine at the University of Ottawa. She continued her training in Medical Oncology in Ottawa, followed by a fellowship year in Clinical Research with the National Cancer Institute of Canada Clinical Trials Group.

She is the research lead for the breast disease site group at the Ottawa Hospital Cancer Centre, and a member of the IND working group for the Breast Cancer Disease Site Committee of the National Cancer Institute for Canada Clinical Trials Group. Her areas of research interest include breast cancer, and treatment related toxicities with a particular interest in cardiotoxicity. She is the founder of the Ottawa Cardiac Oncology Program as well as the Canadian Cardiac Oncology Network, organizations dedicated to improving our understanding of how cancer treatments impact cardiovascular health with the ultimate goal of preventing cardiotoxicity. She established the first multidisciplinary cardio-oncology clinic in Canada in 2008 and since that time has travelled around the world (India, China, Chile) assisting other centers in establishing similar clinics. She is active in cardio-oncology education, having co-authored 3 book chapters  in cardio-oncology (2016/2017) and 3 position statements/guidelines (Canadian Cardiology Society, American Society of Clinical Oncology, European Society of Cardiology).

Professor Helena Earl completed a PhD in Breast Cancer in 1985 and specialist training in Medical Oncology with General Internal Medicine at UCLH in 1991. In 1992 she joined the University of Birmingham and was Director of the Cancer Research UK Clinical Trials Unit, moving to the University of Cambridge, Department of Oncology in 1996. She is active in clinical and translational research and leads NCRN clinical trials in breast cancer (NEAT, tAnGo, Neo-tAnGo, ARTemis, PERSEPHONE, and PARTNER). 

Professor Earl holds grant funding from Cancer Research UK, the NIHR HTA, and pharmaceutical partners. She is a PI in the Cancer Research UK Cambridge Cancer Centre, NIHR BRC, ECMC, CCTC, and Cambridge Breast Cancer Research Unit. She is an active member of the Cambridge Trials Methodology Group developing linked Bayesian Adaptive Randomised (BAR) designs, with biomarkers and new treatments, integrating early biomarkers of response into these designs. Professor Earl has published her research in cardio-oncology from the PERSEPHONE Trial of adjuvant trastuzumab duration.

Dr Mark Harbinson is Senior Lecturer in the Centre for Medical Education, School of Medicine, Dentistry and Biomedical Science, Queen’s University Belfast and Consultant Cardiologist, Belfast Trust. He graduated from Queen’s University Belfast and trained in cardiology in Northern Ireland and at Imperial College/Royal Brompton Hospital in London. His clinical interests include heart failure and cardiac imaging (nuclear cardiology, CMR and echocardiography), and he has supervised several MD and PhD students in these areas. 

He is past president of the British Nuclear Cardiology Society. He runs a cardio-oncology service within Belfast Trust, which is the regional centre for cancer management in Northern Ireland. He is a member of the Committee of the British Cardio-Oncology Society.

Dr. Lenihan, has been active in clinical research in cardiology, and specifically in heart failure, for nearly 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer.

His current projects include early phase clinical trials in heart failure, including the recently presented Phase 1 trial of GGF2 in cooperation with Acorda, Inc. As the Director of Clinical Research in the Division of Cardiovascular Medicine, Dr Lenihan is managing over 100 clinical trials in conjunction with all of VHVI faculty and continues to enhance and foster collaboration among a host of colleagues both internally and throughout the world. He is the current president (US/Canada) of the International CardiOncology Society, a professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

Dr. Alexander Lyon is a Senior Lecturer in Cardiology at Imperial College London and a Consultant Cardiologist at the Royal Brompton Hospital. His clinical interests are in the field of heart failure, cardio-oncology including chemotherapy cardiomyopathy and the cardiovascular complications of modern cancer therapies, Takotsubo syndrome, and the development of novel therapeutics including gene therapy for chronic heart failure.

Alex is the clinical lead for the Cardio-Oncology service at the Royal Brompton Hospital since 2011, specialising in surveillance and cardioprotection from modern cancer drugs, risk stratification and treatment of all cardiac complications of cancer treatment. Alex is the current president of the British Cardio-Oncology Society (formerly the UK Cardio-Oncology Consortium) and he is the cardiology advisor to the charity Macmillan Cancer. Alex was recently appointed chair of the European Society of Cardiology Heart Failure Association Cardio-Oncology Study Group and he is a co-author of their ESC Position Statement on Cardio-Oncology. He is a member of the International Cardio-Oncology Society and is co-chair of the 2017 ICOS-BCOS hosted Global Cardio-Oncology Summit in London.

Charlotte Manisty is a Senior Lecturer at University College London and a Consultant Cardiologist at the Barts Heart Centre and University College Hospitals, London. She specialises in heart failure and cardiac imaging, and has set up and leads the cardio-oncology service at Barts. Her medical training was undertaken at Oxford University and Imperial College, and she was awarded a Wellcome Trust Fellowship for her PhD in cardiorespiratory physiology in heart failure.   

Current research interests include optimising imaging acquisition and analysis methods for identifying patients at risk of developing heart failure, using MRI-based scar imaging to improve ablation in patients with ventricular arrhythmias, and understanding and treating patients with cardiac problems arising from cancer therapies with a particular interest in multiple myeloma. She has also completed a study commissioned by the Medicines and Health Regulatory Authority to assess the risk of cardiotoxicity related to metal-on-metal hip implants. She receives funding for her work from British Heart Foundation, Barts Charity and the National Institute for Health Research, and supervises several PhD students. She is author of over 60 publications and book chapters, and is regularly invited to speak both Nationally and at International conferences.  

Professor McDonagh qualified from the University of Edinburgh and completed her internal medicine training there. She trained in Cardiology at the Western Infirmary in Glasgow. Her main research was on the epidemiology of Left Ventricular Dysfunction and Natriuretic Peptides hormones.  

Subsequently she was appointed as a Senior Lecturer at the University of Glasgow and Glasgow Royal Infirmary where she ran the Heart Failure Service and was the Cardiologist involved in the Heart Transplant Programme (1999-2004). Following this she was a Consultant Cardiologist at the Royal Brompton Hospital, London (2004-2011) where led the Heart Failure Service, before moving to King's College Hospital to head up the Heart Failure Programme. Her main research interests are in novel biomarkers for heart failure and the delivery of heart failure services. She is a past Chair of the British Society for Heart Failure a Past Chair of the Clinical Section of the Heart Failure Association of the European Society of Cardiology. She is the Clinical Lead for the National Heart Failure Audit.

Dr John McGowan is a Cardiology Specialist Trainee in the north west of England. He studied medicine at the University of Manchester and attained a Cardiology National Training Number in 2012. His interests are in heart failure and the effects of cancer treatment on the cardiovascular system. He is currently undertaking research at The Hatter Cardiovascular Institute, University College London, to be submitted for an MD(Res). 

He is investigating potential cardioprotective strategies against anthracycline-induced cardiotoxicity. John is the Trainee Representative of the British Cardio-Oncology Society.

Dr Plummer is a consultant cardiologist at the Freeman Hospital in Newcastle upon Tyne. His clinical work focuses on cardiac implantable electronic device therapies but he also has a major clinical and research interest in cardiovascular effects of cancer treatments. He has co-written cardio-oncology guidance in 3 areas, given advice on more than 50 clinical trials and co-founded the British Cardio-Oncology Society in 2014 where he is Secretary and wrote/published BC-OS.org.

He trained in Bristol where he gained a PhD, St John's College Oxford where he completed his medical degree and in Newcastle where he undertook cardiology training. He is also involved in medical education from interviewing medical students to being the cardiology training programme director in the North East and serving on the exam board for the European General Cardiology Examination.

Dr. Sanjay Prasad is a consultant cardiologist at the Royal Brompton Hospital and Reader at the National Heart and Lung Institute, Imperial College, London. His areas of clinical interest include Cardiomyopathy and heart failure. In addition to his clinical work, he leads a research programme focused on clinical outcomes in risk stratification by CMR with a particular focus on the detection and significance of myocardial fibrosis.

John Radford is Professor of Medical Oncology and Director of Research at The Christie Hospital, Manchester. Research interests are focused on developing and testing new ways of treating lymphoma and monitoring the effectiveness of these treatments using novel biomarkers, studying late effects of chemotherapy on fertility, heart function and the risk of second cancers and investigating how best to prevent or minimise the impact of these in people cured of lymphoma. 

John is chair of the UK National Cancer Research Institute (NCRI) Lymphoma Clinical Studies Group, a member NCRI Hodgkin Lymphoma sub-group and chief investigator for many national and international trials.

Simon Ray graduated in Pharmacology (1980) and Medicine (1983) from Bristol University. After early training in general medicine he completed an MD as a BHF funded research fellow with Professor Henry Dargie in Glasgow and then undertook specialist cardiology training in Newcastle, Liverpool and Vancouver. He was appointed consultant cardiologist at the University Hospitals of South Manchester in 1995 and Honorary Professor of Cardiology at the University of Manchester in 2011.

He has served as the President of the British Society of Echocardiography, Vice-President for Clinical Standards of the British Cardiovascular Society and President of the British Heart Valve Society.

Dr Stuart Rosen is Consultant Cardiologist, Royal Brompton and London Northwest Healthcare Hospitals and Reader in Cardiology, National Heart and Lung Institute, Imperial College London; United Kingdom. He received his medical undergraduate education at Pembroke College, Cambridge and at Charing Cross and Westminster Medical School. His specialist cardiology training was at Charing Cross, Hammersmith and St Mary’s Hospitals.

In clinical practice, Dr Rosen is a general adult cardiologist and has specialist expertise in heart failure, syncope and hypertension. His technical skills include transoesophageal echocardiography, stress echo, tilt testing and autonomic assessment, as well as ultrafiltration for decompensated heart failure. Dr Rosen had a pivotal role in setting up the UK’s first cardio-oncology unit, at the Royal Brompton Hospital, to provide bespoke care for patients at risk of cardiotoxicity or who have developed cardiac problems as a consequence of their anti-cancer treatment. He is Founding Treasurer of the British Cardio-Oncology Society. Dr Rosen has a programme of translational research focused on: Role of cardiac autonomic dysfunction in pathophysiology of cardiac disease; Origins of cardiac pain [member of an international task force on complex cardiac pain syndromes]; Mechanisms of heart injury in cancer patients. He is also cardiologist to the MRC’s Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial, a multi centre study of cardiovascular outcomes in prostate cancer patients treated with transcutaneous oestrogen patches compared with LHRH analogues. Dr Rosen has a busy managerial role as Clinical Director of Medicine at LNW Hospitals. He also has extensive teaching commitments, in medicine, cardiology, ethics and law for medical undergraduates and supervises postgraduates, MD and PhD students. Dr Rosen is author of more than 70 peer reviewed papers, plus review articles, editorials, abstracts, nine book chapters two books.

Professor Rod Skinner has been a Consultant in Paediatric and Adolescent Oncology / BMT at the Great North Children’s Hospital, Royal Victoria Infirmary, Newcastle upon Tyne since January 1996, and is an Honorary Professor of Childhood Cancer, Northern Institute of Cancer Research, Newcastle University. He qualified in Birmingham in 1983, trained initially in general paediatrics and then in paediatric haematology/oncology and BMT in Newcastle, with further BMT experience in the Pediatric BMT Program, Minneapolis, USA. 

He was awarded a PhD by Newcastle University in 1995 for his research thesis into chemotherapy-induced nephrotoxicity in children with cancer. He is the clinical lead in Newcastle for paediatric haematology allogeneic haemopoietic stem cell transplantation, long-term follow-up (LTFU), and bone marrow failure, and has a busy practice in paediatric / adolescent leukaemia. His research interests include late adverse effects of childhood cancer treatment, especially nephrotoxicity, and LTFU of childhood cancer survivors. He has played a leading role in the development of evidence-based, internationally-harmonised LTFU surveillance guidelines. He is a member of the UK Children’s Cancer and Leukaemia Group, with leading roles in the Late Effects Group (current chair), Supportive Care Group (chair 2003-08) and BMT Group (chair 2008-2012). He was a National Clinical Advisor in the NHS National Cancer Survivorship Initiative (2008-2012). He was one of the three instigators and founding members in 2008 of PanCare (Pan-European Network for Care of Survivors after Childhood and Adolescent Cancer), and remains on its Executive Board.

Dr Susannah Stanway is a Consultant in Medical Oncology at The Royal Marsden NHS Foundation Trust. Having qualified from Bristol University in 1998, she obtained an MD thesis for her work on Steroid Sulphatase Inhibition in postmenopausal patients with Breast Cancer from Imperial College in 2009; her oncology training was undertaken at UCLH and The Royal Marsden NHS Foundation Trust. 

She has been working at consultant level since 2012, both in the Acute Oncology Service at Croydon University Hospital and in the Royal Marsden NHS Foundation Trust’s Breast Unit. Along with actively recruiting patients to the large portfolio of research studies in the Breast Unit, her research interest is predominantly focused on Cancer Survivorship. This includes the area of cardio-oncology, in collaboration with amongst others, the Cardio-Oncology Group at the Royal Brompton Hospital and the London School of Hygiene and Tropical Medicine; treatment-induced Hot Flushes, where she sits on the NCRI Symptom Management Working Group; sexual and psychological consequences of cancer and has completed an MSc thesis on Risk Stratification to Guide Follow up after Childhood Malignancy. She co-chairs the Royal Marsden NHS Foundation Trust’s Living With and Beyond Cancer Committee; sits on the Royal Marsden Partners Survivorship pathway and has set up a pan-London multi-disciplinary survivorship research group; she leads the Living with and Beyond Cancer Module on the Institute of Cancer Research (ICR) MSc course; and has been actively involved with the Royal Marsden NHS Foundation Trust’s Young Women’s Breast Cancer Program since its inception; She has a personal interest in cancer control in low-middle income countries and she sits on the editorial board of ASCO’s Journal of Global Oncology, leads a sub-module on Cancer in Low-Middle Income Countries on the ICR MSc course and actively contributes to oncology education in East Africa with the Royal College of Physicians. She is immediate past president of the Oncology Section at the Royal Society of Medicine.

Dr Wright completed early postgraduate training and MD research in Leeds, prior to moving to Liverpool for completion of his training. A keen interest in cardiac dysfunction and device therapy led to his appointment as one of the first device therapists in the UK in 2004. As service lead he has developed one of the largest single centre complex device services in Europe, combining both comprehensive implantation and extraction facilities. 

Involvement with innovative therapies has put Dr Wright at the forefront of SICD development and autonomic modulation evaluation. More recently Dr Wright has developed an interest in the management of cardio-oncology patients particularly those with breast tumours. He is a present developing a strategic service plan for the Cheshire and Merseyside region.